MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
21.94
-2.45
-10.05%
After Hours: 21.98 +0.04 +0.18% 19:26 02/07 EST
OPEN
24.24
PREV CLOSE
24.39
HIGH
24.28
LOW
21.59
VOLUME
232.50K
TURNOVER
--
52 WEEK HIGH
29.82
52 WEEK LOW
7.48
MARKET CAP
386.47M
P/E (TTM)
101.25
1D
5D
1M
3M
1Y
5Y
1D
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
NASDAQ · 1d ago
Insider Sale: EVP & Chief Financial Officer of $RIGL Sells 1,734 Shares
NASDAQ · 1d ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Simply Wall St · 2d ago
Weekly Report: what happened at RIGL last week (0127-0131)?
Weekly Report · 5d ago
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
NASDAQ · 01/30 16:48
Weekly Report: what happened at RIGL last week (0120-0124)?
Weekly Report · 01/27 09:04
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/23 12:05
Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Dow Jones · 01/22 18:31
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.